Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Comparison of large-scale human brain functional and anatomical networks in schizophrenia.

Nelson BG, Bassett DS, Camchong J, Bullmore ET, Lim KO.

Neuroimage Clin. 2017 May 14;15:439-448. doi: 10.1016/j.nicl.2017.05.007. eCollection 2017.

2.

The effect of COMT Val158Met and DRD2 C957T polymorphisms on executive function and the impact of early life stress.

Klaus K, Butler K, Durrant SJ, Ali M, Inglehearn CF, Hodgson TL, Gutierrez H, Pennington K.

Brain Behav. 2017 Apr 12;7(5):e00695. doi: 10.1002/brb3.695. eCollection 2017 May.

3.

The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment.

Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH, Howes OD.

Mol Psychiatry. 2017 May;22(5):666-679. doi: 10.1038/mp.2017.16. Epub 2017 Mar 14. Review.

4.

Patients with schizophrenia show aberrant patterns of basal ganglia activation: Evidence from ALE meta-analysis.

Bernard JA, Russell CE, Newberry RE, Goen JR, Mittal VA.

Neuroimage Clin. 2017 Feb 11;14:450-463. doi: 10.1016/j.nicl.2017.01.034. eCollection 2017.

5.

Insights About Striatal Circuit Function and Schizophrenia From a Mouse Model of Dopamine D2 Receptor Upregulation.

Simpson EH, Kellendonk C.

Biol Psychiatry. 2017 Jan 1;81(1):21-30. doi: 10.1016/j.biopsych.2016.07.004. Epub 2016 Jul 14. Review.

PMID:
27720388
6.
7.

Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A.

Biol Psychiatry. 2017 Jan 1;81(1):31-42. doi: 10.1016/j.biopsych.2016.03.2104. Epub 2016 Mar 31. Review.

PMID:
27206569
8.

Candidate gene networks and blood biomarkers of methamphetamine-associated psychosis: an integrative RNA-sequencing report.

Breen MS, Uhlmann A, Nday CM, Glatt SJ, Mitt M, Metsalpu A, Stein DJ, Illing N.

Transl Psychiatry. 2016 May 10;6:e802. doi: 10.1038/tp.2016.67.

9.

Hyperactivity of caudate, parahippocampal, and prefrontal regions during working memory in never-medicated persons at clinical high-risk for psychosis.

Thermenos HW, Juelich RJ, DiChiara SR, Mesholam-Gately RI, Woodberry KA, Wojcik J, Makris N, Keshavan MS, Whitfield-Gabrieli S, Woo TU, Petryshen TL, Goldstein JM, Shenton ME, McCarley RW, Seidman LJ.

Schizophr Res. 2016 May;173(1-2):1-12. doi: 10.1016/j.schres.2016.02.023. Epub 2016 Mar 7.

10.

Altered Cortico-Striatal Connectivity in Offspring of Schizophrenia Patients Relative to Offspring of Bipolar Patients and Controls.

Solé-Padullés C, Castro-Fornieles J, de la Serna E, Romero S, Calvo A, Sánchez-Gistau V, Padrós-Fornieles M, Baeza I, Bargalló N, Frangou S, Sugranyes G.

PLoS One. 2016 Feb 17;11(2):e0148045. doi: 10.1371/journal.pone.0148045. eCollection 2016.

11.

Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing.

Bendfeldt K, Smieskova R, Koutsouleris N, Klöppel S, Schmidt A, Walter A, Harrisberger F, Wrege J, Simon A, Taschler B, Nichols T, Riecher-Rössler A, Lang UE, Radue EW, Borgwardt S.

Neuroimage Clin. 2015 Sep 30;9:555-63. doi: 10.1016/j.nicl.2015.09.015. eCollection 2015.

12.

Assessing brain structural associations with working-memory related brain patterns in schizophrenia and healthy controls using linked independent component analysis.

Brandt CL, Doan NT, Tønnesen S, Agartz I, Hugdahl K, Melle I, Andreassen OA, Westlye LT.

Neuroimage Clin. 2015 Aug 21;9:253-63. doi: 10.1016/j.nicl.2015.08.010. eCollection 2015.

13.

Altered G Protein Coupling in Olfactory Neuroepithelial Cells From Patients With Schizophrenia.

Borgmann-Winter KE, Wang HY, Ray R, Willis BR, Moberg PJ, Rawson NE, Gur RE, Turetsky BI, Hahn CG.

Schizophr Bull. 2016 Mar;42(2):377-85. doi: 10.1093/schbul/sbv129. Epub 2015 Sep 15.

14.

Neural Dysfunction in Cognitive Control Circuits in Persons at Clinical High-Risk for Psychosis.

Colibazzi T, Horga G, Wang Z, Huo Y, Corcoran C, Klahr K, Brucato G, Girgis R, Gill K, Abi-Dargham A, Peterson BS.

Neuropsychopharmacology. 2016 Apr;41(5):1241-50. doi: 10.1038/npp.2015.273. Epub 2015 Sep 10.

15.

Computational Psychiatry: towards a mathematically informed understanding of mental illness.

Adams RA, Huys QJ, Roiser JP.

J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):53-63. doi: 10.1136/jnnp-2015-310737. Epub 2015 Jul 8. Review.

16.

Glutamate and dopamine in schizophrenia: an update for the 21st century.

Howes O, McCutcheon R, Stone J.

J Psychopharmacol. 2015 Feb;29(2):97-115. doi: 10.1177/0269881114563634. Epub 2015 Jan 13. Review.

17.

Translating the MAM model of psychosis to humans.

Modinos G, Allen P, Grace AA, McGuire P.

Trends Neurosci. 2015 Mar;38(3):129-38. doi: 10.1016/j.tins.2014.12.005. Epub 2014 Dec 30. Review.

18.

Informed consent in the psychosis prodrome: ethical, procedural and cultural considerations.

Morris SE, Heinssen RK.

Philos Ethics Humanit Med. 2014 Nov 18;9:19. doi: 10.1186/1747-5341-9-19. Review.

19.

Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia.

Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, Gallego JA, Kane JM, Szeszko PR, Malhotra AK.

JAMA Psychiatry. 2015 Jan;72(1):5-13. doi: 10.1001/jamapsychiatry.2014.1734.

20.

Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.

Salavati B, Rajji TK, Price R, Sun Y, Graff-Guerrero A, Daskalakis ZJ.

Schizophr Bull. 2015 Jan;41(1):44-56. doi: 10.1093/schbul/sbu132. Epub 2014 Sep 22. Review.

Supplemental Content

Support Center